RE:RE:RE:RE:RE:RE:Meaningful target price increaseJust to put things into perspective. There was no press release on the new target price from Mackie Research Capital. Echelon , Canaccord and National Bank Financial were probably invited but to date we have no news from them. The presentation from Theratechnologies shows good numbers but the catalyst will be the secondary end point results and the initiation of the FDA request. Except for Clarus and Raymond James which I dont see often, the usual brokers were there today. Volume was good, but I suspect that it was the same gang of investors and traders that usually play this stock.